Engineered Inflammation-Triggering Macrophages (MacTrigger) Synergize Anti-CD47 Immunotherapy While Sparing Normal Tissues.
CD47 has attracted considerable attention as a therapeutic immune checkpoint target; however, its clinical efficacy as monotherapy remains limited, mainly due to an M2-rich tumor environment. These limitations highlight the need for combination strategies capable of achieving synergistic anti-tumor effects. We previous...